Fig. 5: Prognostic significance of TP53 alterations in pediatric AML.
a Forest plots showing multivariate Cox regression analysis on EFS and OS. Variables with P < 0.05 in univariate analysis were included in the multivariate analysis with adjustment for the treatment protocol used (the modified United Kingdom Medical Research Council AML 12 protocol served as the reference) and stem cell transplantation at first remission. Squares represent the hazard ratios and horizontal lines extend from the lower to the upper limit of the 95% confidence intervals (CI). Dotted vertical lines represent no effect (hazard ratio of 1). WBC presentation white blood cell, CR complete remission, SCT stem cell transplantation. b Kaplan–Meier analysis of EFS and OS based on cytogenomic features in pediatric AML patients. High-risk fusions (HRf) include those of NUP98, KMT2A::MLLT10, KMT2A::AFDN, DEK::NUP214, FUS::ERG, and CBFA2T3::GLIS266,67. Other adverse include complex karyotype, −7, −5, del(5q), del(12p), FLT3-ITD, and WT1 mutations66. c Risk stratification of pediatric AML patients according to the three-factor scoring model. Patients were stratified into three risk groups (low, intermediate, and high) based on their risk scores.
